Whether the 16% hit that AstraZeneca’s (LSE: AZN) share price took last week on the setback in its Mystic lung cancer trial was a market over-reaction or not, the damage will be hard to repair.
Other news from its lung cancer research on Monday has at least helped to start the healing process, bumping the Anglo-Swedish pharma major’s share price back up by nearly 2% in five hours of trading, to £45.76 ($60.05).
"Imfinzi is the first immuno-oncology medicine to show a clinically-significant benefit in this earlier, non-metastatic setting"
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze